'Artificial Retina' to Restore Age-Related Vision Loss Commercialized in Europe for the First Time
Implanting a Chip in the Retina and Using Special Glasses
Targeting Patients with Age-Related Macular Degeneration
An "artificial retina," which is a thin semiconductor chip implanted under the retina to partially restore lost vision, will be commercialized in Europe for the first time.
A thin semiconductor chip implanted under the retina to partially restore lost vision, called the "artificial retina," will be commercialized in Europe. Science Corporation
View original imageScience Corporation, a U.S. startup, announced on July 22 (local time) that its artificial retina "PRIMA" has received CE certification for medical devices from the European Union (EU). CE certification means that the product meets the EU's safety and performance standards, allowing it to be sold in the European market.
The company plans to conduct its first patient implant surgery in Germany this September. Max Hodak, CEO of Science Corporation, stated, "Our goal is to implant the device in dozens of patients this year and in about 200 patients next year." According to the company, the price of the device has not yet been determined, and it is expected to vary depending on region and insurance provider. The company is also in discussions with the U.S. Food and Drug Administration (FDA) for a U.S. launch next year.
The artificial retina "PRIMA" targets patients who have lost the ability to read text or recognize faces due to the loss of photoreceptors in the central part of the retina caused by age-related macular degeneration. Age-related macular degeneration is the most common cause of vision loss among the elderly. The condition leads to the degeneration of part of the retina, impairing the ability to see straight ahead. While treatment can slow its progression, there is currently no cure. "PRIMA" can be used as an adjunct therapy for the advanced stage of age-related macular degeneration known as geographic atrophy.
The device works for patients in the following way: a chip measuring 2mm by 2mm and 0.03mm thick is implanted under the retina. When the patient wears special glasses equipped with a camera, these glasses capture visual scenes and transmit them to the chip. The chip converts the visual information into electrical signals, which stimulate the remaining retinal ganglion cells. These signals are then sent via the optic nerve to the brain, enabling the patient to perceive images.
The results of the clinical trial were published last year in the medical journal "The New England Journal of Medicine (NEJM)." Among 38 patients enrolled at 17 clinical sites in 5 countries, 84% were able to read letters, numbers, and words using PRIMA. However, PRIMA does not fully restore normal vision. The current images perceived by patients are in black and white and have a limited field of view.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The company explained, "Currently, it is similar to viewing the world through a straw," adding, "Our goal is to improve color and image quality in the future to offer a visual experience that is closer to natural vision."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.